GlassScriptPhysician profile
Paul T Guidry
NPI 1700143237
$1,932.55
in general payments reported to CMS, 2019-2025
28 companies · $711 in 2025
The $711 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.80 · 2020: $48.15 · 2021: $43.90 · 2022: $32.02 · 2023: $234 · 2024: $774 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $549.85 | 2023-2025 | Evenity, Repatha, Otezla |
| Lundbeck LLC | $184.05 | 2023-2025 | Rexulti, Vyepti |
| Lilly USA, LLC | $134.25 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $107.41 | 2019-2025 | |
| Cleerly, INC. | $83.92 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Dexcom, INC. | $78.45 | 2024-2025 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $68.12 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $67.17 | 2019-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $64.04 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $61.29 | 2019-2021 | |
| Antares Pharma, INC. | $55.32 | 2025 | Xyosted |
| Exact Sciences Corporation | $51.54 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $50.10 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Itamar Medical INC | $49.33 | 2024 | Watchpatone |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.08 | 2025 | Caplyta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34.81 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $30.53 | 2023 | Imbruvica |
| Recor Medical INC | $28.33 | 2025 | Paradise Ultrasound Renal Denervation System |
| Cvrx, INC. | $22.60 | 2024 | Barostim Neo System |
| Glaxosmithkline, LLC. | $21.67 | 2023 | Arexvy, Shingrix |
| Tolmar, INC. | $21.27 | 2025 | Jatenzo |
| Phathom Pharmaceuticals, INC. | $20.36 | 2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $19.84 | 2020 | |
| Harmony Biosciences LLC | $17.85 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.30 | 2023 | Nuedexta |
| Astellas Pharma US INC | $16.82 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.81 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Guidry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.